RLA8 is an orally available and potent agonist of peroxisome proliferator-activated receptors (PPARs)-α/γ/δ and G-protein-coupled receptor 40 (GPR40). RLA8 reverses the proregression of pathological changes such as hepatic lipid accumulation, steatosis, inflammation and fibrosis in mice models of nonalcoholic steatohepatitis (NASH). Also, it improves serum HDL cholesterol, reduce hepatic free fatty acid and triglyceride levels, and alleviate insulin resistance.
orally available and potent agonist for PPARs-α/γ/δ and GPR40 that exhibits efficacy to reverse nonalcoholic steatohepatitis and fibrosis
Storage Class
11 - Combustible Solids
wgk_germany
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
Choose from one of the most recent versions:
Certificates of Analysis (COA)
Lot/Batch Number
It looks like we've run into a problem, but you can still download Certificates of Analysis from our Documents section.
The Journal of pharmacology and experimental therapeutics, 369(1), 67-77 (2019-02-13)
Nonalcoholic fatty liver disease (NAFLD) is a very common chronic hepatic disease, with nonalcoholic steatohepatitis (NASH) as a major and severe subcategory that can lead to cirrhosis and hepatocellular carcinoma, and thereby to a high mortality rate. Currently, there has
Questions
Reviews
★★★★★ No rating value
Active Filters
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
